GCase allosteric modulator with Phase 1b durability data heads into Phase 2 — runway runs out before any registrational read

Gain Therapeutics is a clinical-stage company developing a targeted drug for Parkinson's disease that is not yet approved.

Gain is developing rexaceract and GT-02287, small molecules that stabilize GCase to slow neurodegeneration in Parkinson's disease, with nine-month Phase 1b data showing durable MDS-UPDRS stability and 81% GluSph reduction in high-baseline patients. The thesis hinges on whether final Phase 1b results plus Phase 2 initiation are compelling enough to attract a partner or non-dilutive funding, because $13M in cash at $4.7M quarterly burn reaches only Q2 2027. Runway almost certainly does not cover Phase 2 data, making a financing event the near-term gating risk before the science can be tested at scale.